This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Jane M. McGregor, MRCP
Department of Dermatology Royal Free Hospital Pond Street London NW3 2QG, England

David A. Levison, FRCPath; Donald M. MacDonald, FRCPath
London, England

Arch Dermatol. 1994;130(4):518.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

p53 Immunostaining in Dermatopathology

Cristofolini et al¹ describe p53 immunostaining in occasional benign melanocytic nevi and conclude that this observation greatly hinders the diagnostic use of p53 immunostaining in dermatopathology. This interpretation is in danger of missing the point. At best, p53 immuno-staining may be seen in approximately 50% of nonmelanoma skin cancers, including keratoacanthomas,²which renders it almost useless as a marker of the malignant phenotype. Even in melanoma, where a higher prevalence of p53 immunoreactivity has been reported in some studies,^3,4 strong positive staining is predominantly seen in advanced lesions where the distinction between benign and malignant is not likely to be a problem. Surely we should not be considering p53 immunoreactivity as a diagnostic tool but as a potential marker of tumor behavior? Recent evidence suggests p53 positivity in certain malignancies is associated with poor patient survival, and in this respect it deserves our . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?